Amplia Therapeutics Ltd has released a press release.
FDA Clearance - MIS416 Investigational New Drug Application
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Preliminary Final Report - Year Ended 31 March 2017
- Appendix 4C - March 17 Quarter Statement of Cash Flows
- Completion of Phase 2B Trial of MIS416
- Private Placement to raise Additional Working Capital
- Phase 2B Trial of MIS416 on Schedule to Complete April 2017
Later from Amplia Therapeutics
- Top-Line Results for Trial of MIS416
- No Change in Trial Outcome Following Additional Analysis
- App 4C - Quarterly Statement of Cashflows - June 2017 Qtr
- Corporate Update
- Appendix 4C - September 2017 Quarter Cashflows
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics